Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.65 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.65 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.54 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 3/20 | 0.53 |
| ▸ | RXRB | P28702 | 3/20 | 0.53 |
| ▸ | RXRG | P48443 | 1/20 | 0.53 |
| ▸ | BCL2 | P10415 | 1/20 | 0.53 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.52 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.51 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29788150 | 1.00 | XDH (0.65) | XDHSLC22A12PDE4APDE4CPDE4D | |
| SCHEMBL5529069 | 0.88 | XDH (0.62) | XDHSLC22A12PDE4APDE4CPDE4D | |
| SCHEMBL7803345 | 0.86 | XDH (0.60) | XDHSLC22A12PDE4APDE4CPDE4D | |
| SCHEMBL20647100 | 0.85 | MAPT (0.56) | XDHSLC22A12MMP12MMP13PTPN5 | |
| SCHEMBL7603613 | 0.84 | RARA (0.55) | XDHSLC22A12PDE4APDE4CPDE4D | |
| SCHEMBL2515129 | 0.84 | EGFR (0.55) | XDHSLC22A12RXRARXRBRXRG | |
| SCHEMBL306753 | 0.83 | KMO (0.65) | XDHSLC22A12RXRARXRBKMO | |
| SCHEMBL27716780 | 0.83 | TRIM24 (0.54) | XDHSLC22A12TRIM24TRIM33RXRA | |
| SCHEMBL5944259 | 0.82 | PTPN5 (0.56) | XDHSLC22A12MMP12MMP13PTPN5 | |
| SCHEMBL307426 | 0.81 | MAP4K4 (0.60) | XDHSLC22A12RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AG (DE) | 2009-01-22 | — | — | US | claimed |
| CN-114773249-A | Compounds, pharmaceutical compositions and methods for treating inflammatory diseases | 艾匹克治疗公司 | 2022-07-22 | — | — | CN | disclosed |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2021-07-27 | — | — | US | disclosed |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2020-11-05 | — | — | US | disclosed |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-09-22 | — | — | US | disclosed |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | EPICS THERAPEUTICS (BE) | 2020-05-14 | — | — | US | disclosed |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | EPICS THERAPEUTICS (BE) | 2020-03-03 | — | — | US | disclosed |
| EP-3610872-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATORY DISEASES | EPICS THERAPEUTICS (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | EPICS THERAPEUTICS (BE) | 2019-10-03 | — | — | US | disclosed |
| EP-3074008-B1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING INFLAMMATION | EPICS THERAPEUTICS (BE) | 2019-09-04 | — | — | EP | disclosed |
| US-20060154922-A1 | Muscarinic agonists | ELILILLY AND COMPANY (US) | 2006-07-13 | — | — | US | disclosed |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | US | disclosed |
| EP-0917530-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2003-02-19 | — | — | EP | disclosed |
| EP-1080075-A4 | PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES | AVENTIS PHARM PROD INC (US) | 2001-06-27 | — | — | EP | disclosed |
| EP-1080075-A1 | PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES | Aventis Pharmaceuticals Products Inc. (US) | 2001-03-07 | — | — | EP | disclosed |
| US-6046210-A | ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-04 | — | — | US | disclosed |
| WO-1999048870-A1 | PIPERIDIDINYL AND N-AMIDINOPIPERIDINYL DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| CN-1224418-A | Tetrahydroisoquinoline derivs. as modulators of dopamine D3 receptors | SMITHKLINE BEECHAM PLC (GB) | 1999-07-28 | — | — | CN | disclosed |
| EP-0917530-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-26 | — | — | EP | disclosed |
| WO-1997043262-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154922-A1 | Muscarinic agonists | CHRM3, CHRM1, CHRM5 | XDH 1926/4885SLC22A12 2849/4885PDE4A 421/4885 |
| US-10781171-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | XDH 2142/4885SLC22A12 2141/4885PDE4A 164/4885 |
| US-20040220191-A1 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | CYP11B2, CYP11B1, CYP1A1 | XDH 127/4885SLC22A12 1160/4885PDE4A 828/4885 |
| US-20200347016-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | XDH 2142/4885SLC22A12 2141/4885PDE4A 164/4885 |
| US-20200148636-A1 | PYRROLIDINE OR THIAZOLIDINE CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AS AGONISTS OF G-PROTEIN COUPLED RECEPTOR 43 (GPR43) | GPR119, GPR65, GPR84 | XDH 1532/4885SLC22A12 1650/4885PDE4A 416/4885 |
| US-11072582-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | XDH 2142/4885SLC22A12 2141/4885PDE4A 164/4885 |
| US-20090023741-A1 | ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | XDH 2867/4885SLC22A12 2365/4885PDE4A 1303/4885 |
| US-10577318-B2 | Substituted pyrrolidines as G-protein coupled receptor 43 agonists | GPR119, GPR52, GPR88 | XDH 2208/4885SLC22A12 2054/4885PDE4A 192/4885 |
| US-20190300478-A1 | SUBSTITUTED PYRROLIDINES AS G-PROTEIN COUPLED RECEPTOR 43 AGONISTS | GPR119, GPR52, GPR88 | XDH 2287/4885SLC22A12 2142/4885PDE4A 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.